BCG难治性T1G3期膀胱癌的治疗

发布时间：2018-05-19 05:49

本文选题：卡介苗 + 难治　；参考：《重庆医科大学》2014年硕士论文

【摘要】：T1G3期膀胱癌是表浅性膀胱肿瘤中级别较高的一种，其高复发率和进展率的生物学特性使得临床治疗十分困难。卡介苗（BacillusCalmette-Guérin,BCG）膀胱内灌注化疗目前已成为T1G3期膀胱癌的一线治疗方法，其中约40-50%的患者BCG治疗失败。全膀胱切除术是BCG治疗失败后的首选治疗方式，对于需要继续保留膀胱治疗的患者，，寻找一种有效的挽救性治疗的方法是所有泌尿外科医师所共同面临的难题。
[Abstract]:T1G3 stage bladder cancer is a kind of superficial bladder tumor with higher grade. Its high recurrence rate and progression rate make clinical treatment very difficult. Intravesical instillation chemotherapy of Bacillus Calmette-Gu 茅 rinn BCG has become a first-line therapy for T1G3 bladder cancer. About 40-50% of the patients have failed in BCG treatment. Total cystectomy is the first choice of treatment after the failure of BCG treatment. For patients who need to retain bladder treatment, it is a common problem for all urologists to find an effective salvage therapy.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.14

【参考文献】